Cancer cells exhibit a variety of structural and biochemical alterations from normal, healthy cells. These changes include abnormal nuclear shape, increased nuclear to cytoplasmic ratio and the presence of additional and abnormal nucleoli. As understanding of the cell structure has expanded, the nuclear matrix has emerged as an integral component of genetic processing and therefore, has become an important cellular entity for the study of malignant transformation. Many different cancers have now been found to have altered proteins in the cell nucleus or surrounding cytoplasm, expression that is closely correlated with the occurrence of cancer.
Onconome’s current oncology product pipeline is focused on the use of nuclear matrix proteins (NMPs) as organ-specific biomarkers indicative of malignant transformation. NMPs control nuclear morphology, determine specific DNA organization and play a central role in gene regulation and DNA replication.
Our highly experienced scientists specializing in immunoassay development work closely with external collaborators proficient in several aspect of proteomic research such as mass spectrometry, protein sequencing and antibody development, to advance our serum, urine and tissue-based enzyme-linked immunosorbent assays.
|
